As we move into the second half of 2025, our preparations for the anticipated Phase 3 readout of DIAGNODE-3 continue at full pace, reinforced by a solid financial base, an expanding organization, and robust progress across all operational fronts.
In a capital market marked by cautious investor sentiment, Diamyd Medical has secured significant new funding under exceptionally favorable conditions. The recently completed...